- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.06. | Incyte to buy blood disorder drug in possibly $2B deal | ||
| 08.06. | J&J to acquire Firefly, maker of 'degrader' antibody drugs, for up to $1B | ||
| 08.06. | ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option | ||
| 08.06. | Precision under pressure: Logistic solutions for nuclear medicine scalability | ||
| 08.06. | Innovation alone is no longer enough in biopharma | ||
| 05.06. | Study data convince Lundbeck to push new migraine drug forward | ||
| 05.06. | Generic drugmakers gain key victory in 'skinny label' patent case | ||
| 05.06. | Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? | ||
| 04.06. | An ADC specialist sinks on safety concerns for blood cancer drug | ||
| 04.06. | Alnylam, Inceptive ink AI deal potentially worth $2B | ||
| 04.06. | A Spanish biotech banks $87M to make differentiated ADCs | ||
| 03.06. | Legend surges on early data for 'in vivo' lymphoma cell therapy | ||
| 03.06. | House bill aims to crack down on China biotech deals | ||
| 03.06. | NewLimit's $435M megaround; Lilly's busy dealmaking week | ||
| 03.06. | Lilly, Ascidian link up in RNA exon editing pact | ||
| 02.06. | Celcuity breast cancer drug misses 'lofty' expectations in ASCO-spotlighted trial | ||
| 02.06. | Eli Lilly issues data sharing ultimatum to 340B hospitals | ||
| 02.06. | Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug | ||
| 02.06. | AbiVax falls as safety worries cloud 'landmark' immune drug results | ||
| 02.06. | ASCO '26: Bispecifics vs. ADCs, a 'RAS' revolution and a step change in prostate cancer | ||
| 02.06. | Why US-manufactured pharmaceutical packaging equipment matters | ||
| 01.06. | RallyBio tries again for reverse merger, this time with Avenzo | ||
| 01.06. | Servier buys into muscular dystrophy with potentially $2.7B deal | ||
| 01.06. | 2026 Orphan Drugs Report: A safe(r) passage amid stormy waters? | ||
| 29.05. | At ASCO, Merck makes case for a 'cornerstone' cancer drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.